Osmosis Investment Management UK Ltd Buys New Shares in DexCom, Inc. $DXCM

Osmosis Investment Management UK Ltd bought a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 9,635 shares of the medical device company’s stock, valued at approximately $649,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. BOKF NA boosted its stake in shares of DexCom by 175.7% during the 4th quarter. BOKF NA now owns 35,314 shares of the medical device company’s stock worth $2,344,000 after acquiring an additional 22,505 shares during the period. Plato Investment Management Ltd bought a new position in shares of DexCom in the second quarter valued at about $782,000. Stephens Investment Management Group LLC raised its holdings in DexCom by 21.1% in the 4th quarter. Stephens Investment Management Group LLC now owns 1,042,801 shares of the medical device company’s stock valued at $69,211,000 after acquiring an additional 181,701 shares during the period. Eurizon Capital SGR S.p.A. bought a new position in shares of DexCom during the fourth quarter worth approximately $3,231,000. Finally, Goodman Advisory Group LLC bought a new position in DexCom during the 4th quarter worth $1,293,000. 97.75% of the stock is owned by institutional investors.

DexCom Trading Down 2.1%

Shares of DXCM stock opened at $89.16 on Wednesday. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $92.59. The stock’s fifty day simple moving average is $78.15 and its 200 day simple moving average is $71.19. The company has a quick ratio of 1.43, a current ratio of 1.73 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $33.65 billion, a P/E ratio of 35.24, a P/E/G ratio of 1.54 and a beta of 1.41.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.61 by $0.09. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The firm had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.29 billion. During the same period last year, the company earned $0.48 earnings per share. The business’s quarterly revenue was up 13.1% on a year-over-year basis. As a group, sell-side analysts predict that DexCom, Inc. will post 2.64 EPS for the current fiscal year.

Insider Transactions at DexCom

In related news, Director Mark G. Foletta sold 4,000 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $74.13, for a total value of $296,520.00. Following the completion of the transaction, the director owned 52,852 shares in the company, valued at $3,917,918.76. This trade represents a 7.04% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,756 shares of DexCom stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $76.32, for a total transaction of $2,042,017.92. Following the sale, the insider owned 328,970 shares in the company, valued at approximately $25,106,990.40. This represents a 7.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 73,035 shares of company stock worth $5,446,673. 0.28% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. JPMorgan Chase & Co. lifted their price objective on DexCom from $65.00 to $82.00 and gave the company a “neutral” rating in a report on Friday, July 31st. Robert W. Baird set a $105.00 target price on shares of DexCom in a report on Friday, July 31st. Stifel Nicolaus set a $95.00 target price on shares of DexCom and gave the stock a “buy” rating in a report on Friday, July 31st. Bank of America reduced their price target on shares of DexCom from $100.00 to $80.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Finally, Citigroup reaffirmed a “buy” rating and set a $88.00 price target (up from $84.00) on shares of DexCom in a report on Friday, July 31st. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $88.71.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.